What do analysts expect the price target to be for AMRIZE LTD (AMRZ)?
18 analysts have analysed AMRZ and the average price target is 60.38 USD. This implies a price increase of 8.8% is expected in the next year compared to the current price of 55.5.
AMRIZE LTD (AMRZ) Forecast, Price Target & Analyst Ratings
NYSE:AMRZ • CH1430134226
Current stock price
55.5 USD
+0.24 (+0.43%)
Last:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for AMRIZE LTD (AMRZ).
Forecast Snapshot
Price Target Details & History
Consensus Price Target and Range
Mean target
$60.38
Upside
+ 8.80%
From current price of $55.50 to mean target of $60.38, Based on 18 analyst forecasts
Low
$45.28
Median
$61.56
High
$71.02
Price Target Revisions
1 Month
N/A
3 Months
N/A
Price Target Summary
18 Wall Street analysts provided a forecast for the next 12 months for AMRZ. The average price target is 60.38 USD. This implies a price increase of 8.8% is expected in the next year compared to the current price of 55.5.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
77.78%
AMRZ was analyzed by 18 analysts. The buy percentage consensus is at 78. So analysts seem to be have mildly positive about AMRZ.
In the previous month the buy percentage consensus was at a similar level.
AMRZ was analyzed by 18 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-05 | JP Morgan | Maintains | Overweight -> Overweight |
| 2026-02-20 | Truist Securities | Maintains | Buy -> Buy |
| 2026-02-19 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2026-02-19 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2026-02-19 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2026-01-29 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2026-01-15 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2026-01-08 | UBS | Maintains | Neutral -> Neutral |
| 2026-01-08 | Citigroup | Maintains | Buy -> Buy |
| 2025-12-08 | RBC Capital | Downgrade | Outperform -> Sector Perform |
| 2025-11-14 | Stephens & Co. | Initiate | Overweight |
| 2025-11-03 | UBS | Maintains | Neutral -> Neutral |
| 2025-11-03 | Citigroup | Maintains | Buy -> Buy |
| 2025-10-30 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-10-17 | Citigroup | Initiate | Buy |
| 2025-10-14 | UBS | Maintains | Neutral -> Neutral |
| 2025-10-08 | Wells Fargo | Initiate | Overweight |
| 2025-10-07 | Barclays | Initiate | Equal-Weight |
| 2025-09-09 | Oppenheimer | Initiate | Outperform |
| 2025-08-26 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-08-08 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-07-15 | JP Morgan | Initiate | Overweight |
| 2025-07-10 | Bernstein | Initiate | Outperform |
| 2025-07-01 | Goldman Sachs | Initiate | Neutral |
| 2025-06-26 | B of A Securities | Initiate | Neutral |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- N/A
Next Earnings Revisions
Revenue (1 Month)
-1.88%
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
-39.44%
Next Earnings Summary
Full Analyst Estimates 2025 - 2033
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 10.726B | 11.677B 8.87% | 11.704B 0.23% | 12.113B 3.49% | 12.655B 4.47% | 13.347B 5.47% | 13.692B 2.58% | 14.492B 5.84% | 15.151B 4.55% | 16.021B 5.74% | 16.772B 4.69% | 17.53B 4.52% | |
| EBITDA YoY % growth | 2.508B | 2.722B 8.53% | 3.015B 10.76% | 3.081B 2.19% | 3.337B 8.31% | 3.594B 7.70% | 3.85B 7.12% | 4.043B 5.01% | 4.24B 4.87% | 4.641B 9.46% | 4.834B 4.16% | 5.068B 4.84% | |
| EBIT YoY % growth | 1.72B | 1.871B 8.78% | 2.126B 13.63% | 2.129B 0.14% | 2.353B 10.52% | 2.591B 10.11% | 2.775B 7.10% | 2.866B 3.28% | 2.969B 3.59% | 3.039B 2.36% | 3.105B 2.17% | 3.207B 3.29% | |
| Operating Margin | 16.04% | 16.02% | 18.16% | 17.58% | 18.59% | 19.41% | 20.27% | 19.78% | 19.60% | 18.97% | 18.51% | 18.29% | |
| EPS YoY % growth | N/A | N/A | N/A | 2.39 | 2.86 19.74% | 3.19 11.64% | 3.55 11.25% | 4.03 13.42% | 4.29 6.58% | 4.64 8.08% | 4.90 5.49% | 5.18 5.83% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| EPS Q2Q % growth |
|---|
| Revenue Q2Q % growth |
| EBITDA Q2Q % growth |
| EBIT Q2Q % growth |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
11.48%
EPS Next 5 Year
11.82%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
4.48%
Revenue Next 5 Year
4.37%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
19.13%
EBIT Next 5 Year
13.72%
AMRIZE LTD / AMRZ Forecast FAQ
What is the number of analysts for AMRZ stock?
The number of analysts covering AMRIZE LTD (AMRZ) is 18.